JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Predictive Value of IL-6 and PDGF-AA for 28-Day Mortality Risk in Critical Ill Patients

  • 0Department of Infectious Diseases and Clinical Microbiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100043, People's Republic of China.
International Journal of General Medicine +

|

May 15, 2025

|

May 15, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Higher levels of interleukin-6 (IL-6) and platelet-derived growth factor AA (PDGF-AA) predict 28-day mortality in critically ill patients. Combining these biomarkers with SOFA scores improves mortality prediction accuracy.

Area Of Science

  • Critical Care Medicine
  • Biomarker Discovery
  • Precision Medicine

Background

  • Prognostic biomarkers are crucial for improving outcomes in critically ill patients.
  • Precision medicine requires accurate identification of factors predicting mortality.
  • Existing prognostic tools may benefit from novel biomarker integration.

Purpose Of The Study

  • To evaluate the prognostic value of interleukin-6 (IL-6) and platelet-derived growth factor AA (PDGF-AA).
  • To assess the predictive capability of IL-6 and PDGF-AA for 28-day mortality in critically ill individuals.
  • To explore the combined predictive power of these biomarkers with established scoring systems.

Main Methods

  • Recruited 199 critically ill patients from an emergency department.
  • Measured IL-6 and PDGF-AA levels using Luminex assay.
  • Calculated SOFA and APACHE II scores and performed correlation, logistic regression, and ROC analyses.

Main Results

  • Elevated IL-6 and PDGF-AA levels were observed in non-survivors (P<0.05).
  • IL-6 and PDGF-AA independently predicted 28-day mortality (OR=1.003, 1.002).
  • Combined IL-6 and SOFA achieved an AUROC of 0.892; IL-6, PDGF-AA, and SOFA achieved 0.905.

Conclusions

  • Serum IL-6 and PDGF-AA levels are important prognostic indicators in critical illness.
  • Combining IL-6 and PDGF-AA with SOFA scores enhances prediction of 28-day mortality.
  • Monitoring these biomarkers can aid in risk stratification and personalized treatment strategies.

Keywords: